Summary
General Electric Company (GE) reported its 2020 fiscal year results, marked by significant impacts from the COVID-19 pandemic, particularly on its Aviation segment. Despite a substantial year-over-year revenue decline, GE demonstrated resilience through cost-saving measures and a notable reduction in borrowings, enhancing its liquidity position with $36.6 billion in cash and cash equivalents. The company completed the divestiture of its BioPharma business for $21.1 billion, contributing to a significant pre-tax gain. However, it also recorded substantial non-cash impairment charges related to goodwill and assets across its Aviation, Power, and Capital segments, largely driven by the pandemic's impact and strategic business exits. GE is actively managing its portfolio and de-leveraging its balance sheet, with consolidated borrowings reduced by $15.8 billion. Looking ahead, GE continues to navigate economic uncertainties while focusing on operational execution and strategic priorities, including advancements in its Renewable Energy and Healthcare segments. The company's ability to manage costs and cash flow, alongside its deleveraging efforts, will be critical for investor confidence in the near to medium term.
Financial Highlights
53 data points| Revenue | $75.83B |
| Cost of Revenue | $60.42B |
| Gross Profit | $15.41B |
| R&D Expenses | $2.56B |
| SG&A Expenses | $12.63B |
| Operating Expenses | $81.26B |
| Operating Income | -$6.11B |
| Net Income | $5.70B |
| EPS (Basic) | $4.63 |
| EPS (Diluted) | $4.63 |
| Shares Outstanding (Basic) | 1.09B |
| Shares Outstanding (Diluted) | 1.09B |
Key Highlights
- 1Total revenues decreased by 16% to $79.6 billion, heavily impacted by COVID-19, especially in the Aviation segment.
- 2GE Industrial net debt decreased by $15.6 billion to $32.3 billion due to debt repayments and increased cash balance.
- 3Completed the sale of BioPharma business for $21.1 billion, recognizing a $12.4 billion pre-tax gain.
- 4Recognized significant non-cash impairment charges totaling $2.5 billion across various segments (Aviation, Capital, Power) due to the pandemic and strategic decisions.
- 5Aviation segment experienced a severe revenue decline of 33% and an 82% drop in profit due to reduced commercial air traffic.
- 6Healthcare segment saw increased demand for certain products like ventilators, partially offsetting declines in other areas.
- 7Ended the year with $36.6 billion in consolidated cash, cash equivalents, and restricted cash, with $20.2 billion in available credit lines, indicating a strong liquidity position.